

CLINICAL CANCER RESEARCH

TABLE OF CONTENTS

HIGHLIGHTS

1991 Selected Articles from This Issue

SPECIAL FEATURES

CCR Translations

1993 **Revisiting Intracavitary Immunotherapy of Cancer**
Fernando Aranda, Iñaki Eguren-Santamaria, Ángela Bella, Pedro Berraondo, and Ignacio Melero
See related article, p. 2038

1996 **Standing Watch: Immune Activation and Failure in Melanoma Sentinel Lymph Nodes**
Amanda W. Lund
See related article, p. 2069

Review

1999 **Expanding Therapeutic Opportunities for Extrapulmonary Neuroendocrine Carcinoma**
Melissa Frizziero, Elaine Kilgour, Kathryn L. Simpson, Dominic G. Rothwell, David A. Moore, Kristopher K. Frese, Melanie Galvin, Angela Lamarca, Richard A. Hubner, Juan W. Valle, Mairéad G. McNamara, and Caroline Dive

CLINICAL TRIALS: TARGETED THERAPY

2020 **Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial**
Valentina Boni, Mary J. Fidler, Hendrik-Tobias Arkenau, Alexander Spira, Funda Meric-Bernstam, Nataliya Uboha, Rachel E. Sanborn, Randy F. Sweis, Patricia LoRusso, Misako Nagasaka, Javier Garcia-Corbacho, Shadia Jalal, James J. Harding, Stella K. Kim, Iris H.C. Miedema, Danielle J. Vugts, Marc C. Huisman, Gerben J.C. Zwezerijnen, Guus A.M.S. van Dongen, C. Willemien Menke van der Houven van Oordt, Song Wang, Tam Dang, Ivan A. Zein, Olga Vasiljeva, Susan K. Lyman, Virginia Paton, Alison Hannah, and Joyce F. Liu

2030 **Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nanogenerator Actinium-225-Lintuzumab**

Todd L. Rosenblat, Michael R. McDevitt, Jorge A. Carrasquillo, Neeta Pandit-Taskar, Mark G. Frattini, Peter G. Maslak, Jae H. Park, Dan Douer, Dragan Cicic, Steven M. Larson, David A. Scheinberg, and Joseph G. Jurcic

CLINICAL TRIALS: IMMUNOTHERAPY

2038 **Phase I Trial Combining Chemokine-Targeting with Loco-Regional Chemoimmunotherapy for Recurrent, Platinum-Sensitive Ovarian Cancer Shows Induction of CXCR3 Ligands and Markers of Type 1 Immunity**
Brian Orr, Haider Mahdi, Yusi Fang, Mary Strange, Ibrahim Uygun, Mainpal Rana, Lixin Zhang, Adria Suarez Mora, Alexandra Pusateri, Esther Elishaev, Chaeryon Kang, George Tseng, William Gooding, Robert P. Edwards, Pawel Kalinski, and Anda M. Vlad
See related commentary, p. 1993

2050 **Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials**
Joaquim Bellmunt, Ronald de Wit, Yves Fradet, Miguel A. Climent, Daniel P. Petrylak, Jae-Lyun Lee, Lawrence Fong, Andrea Necchi, Cora N. Sternberg, Peter H. O'Donnell, Thomas Powles, Elizabeth R. Plimack, Dean F. Bajorin, Arjun V. Balar, Daniel Castellano, Toni K. Choueiri, Stephane Culine, Winald Gerritsen, Howard Gurney, David I. Quinn, Jacqueline Vuky, Nicholas J. Vogelzang, Razvan Cristescu, Jared Lunceford, Assieh Saadatpour, Andrey Loboda, Junshui Ma, Mohini Rajasagi, James Luke Godwin, Blanca Homet Moreno, and Petros Grivas

PRECISION MEDICINE AND IMAGING

2061 **HPV and DNA Methylation Testing in Urine for Cervical Intraepithelial Neoplasia and Cervical Cancer Detection**
Rianne van den Helder, Renske D.M. Steenbergen, Annina P. van Splunter, Constantijne H. Mom, Ming Y. Tjong, Ivonne Martin, Fleur M.F. Rosier-van Dunné, Irene A.M. van der Avoort, Maaike C.G. Bleeker, and Nienke E. van Trommel

TABLE OF CONTENTS

- 2069** **Single-Cell Immune Mapping of Melanoma Sentinel Lymph Nodes Reveals an Actionable Immunotolerant Microenvironment**
Kavitha Yaddanapudi, Bryce F. Stamp, Priyanka B. Subrahmanyam, Andrei Smolenkov, Sabine J. Waigel, Rahul Gosain, Michael E. Egger, Robert C.G. Martin, Robert Buscaglia, Holden T. Maecker, Kelly M. McMasters, and Jason A. Chesney
See related commentary, p. 1996
- 2082** **IL15 and Anti-PD-1 Augment the Efficacy of Agonistic Intratumoral Anti-CD40 in a Mouse Model with Multiple TRAMP-C2 Tumors**
Wei Chen, Richard N. Bamford, Elijah F. Edmondson, and Thomas A. Waldmann
- 2094** **Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer**
Aleksandar Obradovic, Diana Graves, Michael Korrer, Yu Wang, Sohini Roy, Abdullah Naveed, Yaomin Xu, Adam Luginbuhl, Joseph Curry, Michael Gibson, Kamran Idrees, Paula Hurley, Peng Jiang, X. Shirley Liu, Ravindra Uppaluri, Charles G. Drake, Andrea Califano, and Young J. Kim
- 2110** **Transcriptomic Profiling of MSI-H/dMMR Gastrointestinal Tumors to Identify Determinants of Responsiveness to Anti-PD-1 Therapy**
Keigo Chida, Akihito Kawazoe, Toshihiro Suzuki, Masahito Kawazu, Toshihide Ueno, Kazumasa Takenouchi, Yoshiaki Nakamura, Yasutoshi Kuboki, Daisuke Kotani, Takashi Kojima, Hideaki Bando, Saori Mishima, Takeshi Kuwata, Naoya Sakamoto, Jun Watanabe, Hiroyuki Mano, Masafumi Ikeda, Kohei Shitara, Itaru Endo, Tetsuya Nakatsura, and Takayuki Yoshino
- 2118** **Natural History and Characteristics of *ERBB2*-mutated Hormone Receptor-positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case-control Study from AACR Project GENIE**
Michele L. LeNoue-Newton, Sheau-Chiann Chen, Thomas Stricker, David M. Hyman, Natalie Blauvelt, Philippe L. Bedard, Funda Meric-Bernstam, Rinaa S. Punglia, Deborah Schrag, Eva M. Lepisto, Fabrice Andre, Lillian Smyth, Semih Dogan, Celeste Yu, Chetna Wathoo, Mia Levy, Lisa D. Eli, Feng Xu, Grace Mann, Alshad S. Lalani, Fei Ye, Christine M. Micheel, and Monica Arnedos on behalf of AACR Project GENIE Consortium
- 2131** **Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy**
Jiannong Li, Inna Smalley, Zhihua Chen, Jheng-Yu Wu, Manali S. Phadke, Jamie K. Teer, Thanh Nguyen, Florian A. Karreth, John M. Koomen, Amod A. Sarnaik, Jonathan S. Zager, Nikhil I. Khushalani, Ahmad A. Tarhini, Vernon K. Sondak, Paulo C. Rodriguez, Jane L. Messina, Y. Ann Chen, and Keiran S.M. Smalley
- 2147** **Aberrant Activation of Cell-Cycle-Related Kinases and the Potential Therapeutic Impact of PLK1 or CHEK1 Inhibition in Uterine Leiomyosarcoma**
Kosuke Yoshida, Akira Yokoi, Tomofumi Yamamoto, Yusuke Hayashi, Jun Nakayama, Tsuyoshi Yokoi, Hiroshi Yoshida, Tomoyasu Kato, Hiroaki Kajiyama, and Yusuke Yamamoto
- 2160** **Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple Myeloma**
Malin Hultcrantz, Even H. Rustad, Venkata Yellapantula, Allison Jacob, Theresia Akhlaghi, Neha Korde, Sham Mailankody, Alexander M. Lesokhin, Hani Hassoun, Eric L. Smith, Oscar B. Lahoud, Heather J. Landau, Gunjan L. Shah, Michael Scordo, David J. Chung, Sergio Giral, Elli Papaemmanuil, and Ola Landgren
- 2167** **Modulation of the Estrogen/erbB2 Receptors Cross-talk by CDK4/6 Inhibition Triggers Sustained Senescence in Estrogen Receptor- and ErbB2-positive Breast Cancer**
Lucia Viganò, Alberta Locatelli, Adele Ulisse, Barbara Galbardi, Matteo Dugo, Diego Tosi, Carlo Tacchetti, Tiziana Daniele, Balázs Gyórfy, Lorenzo Sica, Marina Macchini, Milvia Zambetti, Stefania Zambelli, Giampaolo Bianchini, and Luca Gianni
- 2180** **Antitumor Activity of a Mitochondrial-Targeted HSP90 Inhibitor in Gliomas**
Shiyong Wei, Delong Yin, Shengnan Yu, Xiang Lin, Milan R. Savani, Kuang Du, Yin Ku, Di Wu, Shasha Li, Hao Liu, Meng Tian, Yaohui Chen, Michelle Bowie, Seethalakshmi Hariharan, Matthew Waitkus, Stephen T. Keir, Eric T. Sugarman, Rebecca A. Deek, Marilyne Labrie, Mustafa Khasraw, Yiling Lu, Gordon B. Mills, Meenhard Herlyn, Kongming Wu, Lunxu Liu, Zhi Wei, Keith T. Flaherty, Kalil Abdullah, Gao Zhang, and David M. Ashley

TABLE OF CONTENTS

CORRECTIONS

- 2196** **Correction: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with *NTRK* Fusion-Positive Solid Tumors**
George D. Demetri, Filippo De Braud, Alexander Drilon, Salvatore Siena, Manish R. Patel, Byoung Chul Cho, Stephen V. Liu, Myung-Ju Ahn, Chao-Hua Chiu, Jessica J. Lin, Koichi Goto, Jeeyun Lee, Lyudmila Bazhenova, Thomas John, Marwan Fakih, Sant P. Chawla, Rafal Dziadziuszko, Takashi Seto, Sebastian Heinzmann, Bethany Pitcher, David Chen, Timothy R. Wilson, and Christian Rolfo

- 2197** **Correction: *Pik3ip1* Is a Negative Immune Regulator that Inhibits Antitumor T-Cell Immunity**
Yichen Chen, Jun Wang, Xi Wang, Xinye Li, Jingjing Song, Juan Fang, Xiangqi Liu, Tao Liu, Dikan Wang, Qunxing Li, Shuqiong Wen, Da Ma, Juan Xia, Liqun Luo, Song Guo Zheng, Jun Cui, Gucheng Zeng, Lieping Chen, Bin Cheng, and Zhi Wang

ABOUT THE COVER

The cover image shows GeoMx digital spatial profiler (DSP) imaging of a human head and neck squamous cell carcinoma section from a patient treated with α PD-1 immunotherapy. Immunofluorescence staining shows the presence of PanCK⁺ tumor cells (*green*), CD8⁺ T cells (*red*), and α SMA⁺ fibroblasts (*yellow*) with nuclei stained in blue. In this study, the authors identified a novel cancer-associated fibroblast subset predictive of α PD-1 immunotherapy response and associated with reduced T-cell exhaustion. For details, see the article by Obradovic and colleagues on page 2094 of this issue.

doi: 10.1158/1078-0432.CCR-28-10-CVR

